A phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) in patients with advanced solid tumours.

Trial Profile

A phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) in patients with advanced solid tumours.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Starpharma
  • Most Recent Events

    • 20 Mar 2014 Status changed from not yet recruiting to recruiting, as per Australian New Zealand Clinical Trials Registry record.
    • 17 Feb 2014 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12614000171617).
    • 23 Jan 2014 Status changed from planning to recruiting, as reported in a Starpharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top